Table I.

IL-12 deficiency is associated with resistance to tumor promoter-induced skin edema in mice^a

Treatments	Dose of tumor promoter (μg)	Skin punch weight (mg)	% lower	Bi-fold skin thickness (mm)	% lower
Acetone (WT)		20.3 ± 1.0b		0.82 ± 0.08
Acetone (IL-12 KO)		20.0 ± 1.0		0.80 ± 0.09
Acute TPA (1×)
WT	5	29.2 ± 1.3		1.13 ± 0.10
IL-12 KO		27.0 ± 1.3c	21	1.00 ± 0.10c	35
Multiple TPA (3×)
WT	5	36.6 ± 1.4		1.26 ± 0.09
IL-12 KO		32.5 ± 1.3c	23	1.11 ± 0.08c	29
Acute mezerein (1×)
WT	5	26.3 ± 2.0		1.05 ± 0.08
IL-12 KO		24.5 ± 1.5c	25	0.94 ± 0.09c	38

WT, wild-type.

^aTumor promoter-induced skin edema was determined by weighing 1.0 cm diameter punch biopsies of treated skin sites that were obtained 6 h after tumor promoter treatment. Bi-fold skin thickness of treated areas of the skin was measured 6 h after tumor promoter application. Mice were topically treated with either TPA or mezerein in 0.2 ml acetone per mouse at the indicated doses of tumor promoters. In the case of TPA, the effect was also evaluated after multiple applications (3×) of TPA. Control mice were treated with vehicle (acetone, 0.2 ml acetone per mouse) alone.

^bMean ± SD of three individual values from each mouse (five mice per group).

^cSignificantly less versus WT mice, P < 0.05.